Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data. - Wikidata - wikimedia - TriplyDB

Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data.

Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data.

http://www.wikidata.org/entity/Q30680371

about

Molecular and cell-based therapies for muscle degenerations: a road under construction Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis.Myocardial Perfusion in Rheumatoid Arthritis Patients: Associations with Traditional Risk Factors and Novel Biomarkers.Reduced risk of all-cancer and solid cancer in Taiwanese patients with rheumatoid arthritis treated with etanercept, a TNF-α inhibitor.Efficacy and safety of etanercept in chronic immune-mediated disease.Etanercept: a review of its use in autoimmune inflammatory diseases.Disease assessment in systemic vasculitis.A European chart review study on early rheumatoid arthritis treatment patterns, clinical outcomes, and healthcare utilization.Immunopathogenesis of systemic lupus erythematosus and rheumatoid arthritis: the role of aberrant expression of non-coding RNAs in T cells.Malignancy Incidence, Management, and Prevention in Patients with Rheumatoid Arthritis.Development and validation of a multivariate predictive model for rheumatoid arthritis mortality using a machine learning approach Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events.Response to: 'Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?' by Nocturne et al.One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review.Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?Changes in T cell effector functions over an 8-year period with TNF antagonists in patients with chronic inflammatory rheumatic diseases.

P2860

Q24568176-3E37961D-8B01-4EB7-B6F9-034608C61EA4 Q26778600-3477609B-E094-4699-83AD-323706FB3CDE Q30240180-69B4C116-15A3-48F8-98F4-603B85BAD058 Q33695937-A3690225-23CE-4F35-8D22-D63BAB5F688B Q37656273-B8AFD456-CA1A-478B-A6AE-B58440588221 Q38198080-A2F931E7-B858-4368-B641-4A884083743D Q38230740-32A0B3AE-0DEB-4C4B-8054-C2E8C8D58E2D Q38348251-185B7237-6E36-4849-8249-A6DA09D9D234 Q38545293-A79DA69C-594B-4566-B908-7148A164A7E4 Q39018269-29EBAE08-7309-486B-A1B3-C9F3E22D878B Q39309064-877020C8-B06D-40A5-AC36-0C9A51936DE7 Q41581523-A251EBC1-38BD-4FB2-9A40-1BE62068F412 Q46339522-329C68A7-38B0-41CB-83F1-EEA24068A9B1 Q48171928-4D3DB894-AEFE-43C5-B882-D8F0D2ECADCB Q49783699-220E58A5-D753-4955-8462-E31D5E7169AA Q50109832-3259ABAE-50AE-4BE7-AA2F-F1CBCD9F08DE Q54546316-20761CAC-8DEC-4C15-AC63-01A355BE136D Q55305483-F8270185-8915-45F5-BBA0-B8DFDFDAF849

P2860

Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data.

http://www.wikidata.org/entity/Q30680371

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

name

Treatment of rheumatoid arthri ...... ospective, observational data.

@ast

Treatment of rheumatoid arthri ...... ospective, observational data.

@en

Treatment of rheumatoid arthri ...... ospective, observational data.

@en-gb

type

label

Treatment of rheumatoid arthri ...... ospective, observational data.

@ast

Treatment of rheumatoid arthri ...... ospective, observational data.

@en

Treatment of rheumatoid arthri ...... ospective, observational data.

@en-gb

prefLabel

Treatment of rheumatoid arthri ...... ospective, observational data.

@ast

Treatment of rheumatoid arthri ...... ospective, observational data.

@en

Treatment of rheumatoid arthri ...... ospective, observational data.

@en-gb

P1433

Q30680371-04C51C53-FE26-4E5C-8AE9-464092863AC2

P1476

Q30680371-DD62BDDD-D4A1-4572-BFD9-A6778F5BDD94

P2093

Q30680371-4590AE02-534F-497F-A7D0-65B87DD6F4FC

Q30680371-5C6E20B2-0FDD-4F31-AC5F-6FDCD919341D

Q30680371-8296C89D-F317-4750-BA21-D01994E757B5

Q30680371-A210D346-0FDC-4684-8AA4-53165D1E7E3D

Q30680371-F59F5B21-E168-478E-BA1C-B37AC61ED51D

Q30680371-FA57BAB6-94D8-4D1F-84E3-11C9B7BF0429

P2860

Q30680371-001BEE66-6685-4CCC-AABA-85A7A1EC235C

Q30680371-102F9BEF-DA51-4264-9F5A-C6C069A36BEC

Q30680371-17DE9D33-7C1C-4940-95A5-E10DEB12C73F

Q30680371-1EE30992-F0C7-4834-874A-F0A94F13D829

Q30680371-4081DBFD-40C6-405F-A731-7D920DBE6F91

Q30680371-49FE3181-1D9D-4F7D-B021-47178B7A88CF

Q30680371-55444C4B-0A1E-41AC-A37B-E29A533E3E8D

Q30680371-5728D111-0834-42C2-A550-CB98BC0BEFE0

Q30680371-57EE5BF0-D8D9-4FEC-B297-3CD4A0992A85

Q30680371-5C8BE55F-7CD2-42D1-BAE2-66001F99A020

P304

Q30680371-0D786A8D-C373-4437-BB5E-9B52558D7370

P31

Q30680371-E376195D-8CF0-4E15-9C8B-0885EAC5E82A

P356

Q30680371-9B2DF0F0-2FC5-4568-86FD-EC2AF93716BC

P433

Q30680371-69BDAD6A-1D9F-45DD-BDE3-BD4CC2A28AA9

P478

Q30680371-419D76DA-CA78-410E-A3C1-9CB2E5D6117B

P50

Q30680371-A080D945-9B97-46FF-9B25-3F3A60F417BF

Q30680371-F82D5488-2DBC-491A-8546-27B0ABF3E526

P577

Q30680371-08C27A87-A9F5-4313-9D44-05DFCB9C1392

P5875

Q30680371-9DDC7206-4E98-4D7E-8249-267B94B37A2B

P6179

Q30680371-8A307DDB-4E75-46DF-8DE2-4D4F08421648

P698

Q30680371-04E70567-85B7-4CAC-8613-F5ACDB30229E

P356

P1433

P1476

Treatment of rheumatoid arthri ...... ospective, observational data.

@en

P2093

Adam Young

http://www.w3.org/2001/XMLSchema#string

Alan Reynolds

http://www.w3.org/2001/XMLSchema#string

Chris D Poole

http://www.w3.org/2001/XMLSchema#string

Christopher Ll Morgan

http://www.w3.org/2001/XMLSchema#string

Craig J Currie

http://www.w3.org/2001/XMLSchema#string

Helen Boyd

http://www.w3.org/2001/XMLSchema#string

P2860

Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies.

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.

No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register

Informed consent in human experimentation before the Nuremberg code.

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with specia

Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation.

Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?

The British Society for Rheumatology biologics register.

Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis.

P304

186-194

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/RHEUMATOLOGY/KET333

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-10-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258059297

http://www.w3.org/2001/XMLSchema#string

P6179

1016644387

http://www.w3.org/2001/XMLSchema#string

P698

24140761

http://www.w3.org/2001/XMLSchema#string